Journal article

Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR)

Krystal Bergin, Cameron Wellard, Bradley Augustson, Rachel Cooke, Hilary Blacklock, Simon J Harrison, Joy Ho, Tracy King, Hang Quach, Peter Mollee, Patricia Walker, Elizabeth Moore, Zoe McQuilten, Erica Wood, Andrew Spencer

BONE MARROW TRANSPLANTATION | SPRINGERNATURE | Published : 2021

Abstract

Supported by clinical trial proven survival benefit, clinical guidelines recommend upfront autologous stem cell transplantation (ASCT) for eligible MM patients. However, reported real-world utilisation is lower than expected (40-60%). We reviewed ASCT utilisation, demographics and outcomes for MM patients (≤70 years, ≥12-month follow-up) enroled onto the Australian/New Zealand MRDR from June 2012 to May 2020. In 982 patients (<65 years: 684, 65-70 years: 298), ASCT utilisation was 76% overall (<65 years: 83%, 65-70 years: 61%, front-line therapy: 67%). Non-ASCT recipients were older (median age: 65 years vs 60 years, p < 0.001), had more comorbidities (cardiac disease: 16.9% vs 5.4%, p < 0.0..

View full abstract

Grants

Funding Acknowledgements

The authors thank the patients, hospitals, clinicians, and research staff at participating institutions for their support of the MRDR. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors; however, the ANZ MRDR has received funding from Amgen, Bristol-Myers Squibb, Celgene, Gilead, Janssen, Novartis, Sanofi and Takeda.